mimmunМедицинская иммунологияMedical Immunology (Russia)1563-06252313-741XSPb RAACI10.15789/1563-0625-2016-4-357-364mimmun-1058Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESЛОКАЛЬНАЯ И СИСТЕМНАЯ ПРОДУКЦИЯ VEGF-А ПРИ ОСЛОЖНЕННОЙ ПРОЛИФЕРАТИВНОЙ ДИАБЕТИЧЕСКОЙ РЕТИНОПАТИИLOCAL AND SYSTEMIC VEGF-А PRODUCTION IN COMPLICATED PROLIFERATIVE DIABETIC RETINOPATHYНероевВ. В.NeroevV. V.

д.м.н., профессор, директор

PhD, MD (Medicine), Professor, Director

ЗайцеваО. В.ZaytsevaO. V.

к.м.н., ведущий научный сотрудник отдела по лечению патологии сетчатки и зрительного нерва

PhD (Medicine), Leading Research Associate, Department for Treatment of Retinal and Optic Nerve Diseases

БалацкаяН. В.BalatskayaN. V.

к.б.н., ведущий научный со.рудник отдела иммунологии и вирусологии

PhD (Biology), Leading Research Associate, Department of Immunology and Virology

КурчаеваЗ. В.KurchaevaZ. V.

аспирант отдела патологии сетчатки и зрительного нерва,

105062, Москва, ул. Садовая-Черногрязская, 14/19

Graduate Student, Department for Treatment of Retinal and Optic Nerve Diseases,

105062, Moscow, SadovayaChernogryazskaya str., 14/19

Kurchaeva1608@mail.ruФГБУ «Московский научно-исследовательский институт глазных болезней им. Гельмгольца» Министерства здравоохранения РФРоссияH. Helmholtz Research Institute of Eye DiseasesRussian Federation201623082016184357364Copyright © Нероев В.В., Зайцева О.В., Балацкая Н.В., Курчаева З.В., 20162016Нероев В.В., Зайцева О.В., Балацкая Н.В., Курчаева З.В.Neroev V.V., Zaytseva O.V., Balatskaya N.V., Kurchaeva Z.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.mimmun.ru/mimmun/article/view/1058

Изучено содержание VEGF-A в сыворотке крови, слезной жидкости, стекловидном теле пациентов при различных клинических вариантах осложненной пролиферативной диабетической ретинопатии (ПДР). Обследованы 50 больных сахарным диабетом (I, II тип), 12 пациентов с регматогенной отслойкой сетчатки и 15 здоровых лиц. Выявлено, что осложненная ПДР ассоциируется с повышением уровня VEGF-A в сыворотке крови и слезной жидкости пациентов по сравнению с та- ковым больных со стабильной ПДР и здоровых лиц, а также высоким содержанием VEGF-A в стекловидном теле, достоверно превосходящим значения концентрации этого цитокина при регматогенной отслойке сетчатки. Наиболее тяжелые клинические проявления осложненной ПДР, интраоперационные геморрагические осложнения ассоциировались с резким повышением VEGF-А в сыворотке крови и стекловидном теле, отражавшим нарушения на локальном и системном уровнях.

VEGF-A contents was studied in blood serum, lacrimal fluid, and vitreous body of patients with different clinical forms of complicated proliferative diabetic retinopathy (PDR). The study included 50 patients with diabetes mellitus (type I, II), twelve patients with rhegmatogenous retinal detachment and fifteen healthy individuals. Complicated PDR was shown to be associated with higher levels of VEGF-A in blood serum and lacrimal fluid of these patients as compared to the cases of stable PDR and healthy individuals, as well as increased VEGF-A concentrations in vitreous humor. Concentrations of this cytokine in vitreous body proved to be significantly exceeded those in rhegmatogenous retinal detachment. Most severe clinical manifestations in complicated PDR and intraoperative hemorrhagic complications were associated with sharp VEGF-A increase in blood serum and vitreous humor, thus reflecting certain disturbances at local and systemic levels.

пролиферативная диабетическая ретинопатияпатогенезвитреоретинальная хирургияVEGF-Aproliferative diabetic retinopathypathogenesisvitreoretinal surgeryVEGF-AReferencesДиагностика и лечение диабетической ретинопатии и диабетического макулярного отека. Федеральные клинические рекомендации (протоколы лечения). М.: ООО «Ассоциация врачей-офтальмологов», 2013. С. 18. [Diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Federal clinical recommendations (treatment protocols)]. Moscow: All-Russian public organization «Association of ophthalmologists», 2013, p. 18.Диагностика и лечение диабетической ретинопатии и диабетического макулярного отека. Федеральные клинические рекомендации (протоколы лечения). М.: ООО «Ассоциация врачей-офтальмологов», 2013. С. 18. [Diagnosis and treatment of diabetic retinopathy and diabetic macular edema. Federal clinical recommendations (treatment protocols)]. Moscow: All-Russian public organization «Association of ophthalmologists», 2013, p. 18.Балашевич Л.И., Бржевский В.В., Измайлов А.С. Глазные проявления диабета. СПб., 2004. C. 382. [Balashevich L.I., Brzhevsky V.V., Izmailov A.S. Ocular manifestations of diabetes]. St. Petersburg, 2004, p. 382.Балашевич Л.И., Бржевский В.В., Измайлов А.С. Глазные проявления диабета. СПб., 2004. C. 382. [Balashevich L.I., Brzhevsky V.V., Izmailov A.S. Ocular manifestations of diabetes]. St. Petersburg, 2004, p. 382.Нероев В.В., Слепова О.С., Зайцева О.В., Курчаева З.В. Особенности локальной и системной продукции эндотелина при осложненной пролиферативной диабетической ретинопатии // Российский офтальмологический журнал, 2015. Т. 8, № 3. С. 31-37. [Neroev V.V., Slepova O.S., Zaytseva O.V., Kurchaeva Z.V. Features of local and systemic production of endothelin in complicated proliferative diabetic retinopathy. Rossiyskiy oftal`mologicheskiy zhurnal = Russian Ophthalmological Journal, 2015, Vol. 8, no. 3, pp. 31-37. (In Russ.)]Нероев В.В., Слепова О.С., Зайцева О.В., Курчаева З.В. Особенности локальной и системной продукции эндотелина при осложненной пролиферативной диабетической ретинопатии // Российский офтальмологический журнал, 2015. Т. 8, № 3. С. 31-37. [Neroev V.V., Slepova O.S., Zaytseva O.V., Kurchaeva Z.V. Features of local and systemic production of endothelin in complicated proliferative diabetic retinopathy. Rossiyskiy oftal`mologicheskiy zhurnal = Russian Ophthalmological Journal, 2015, Vol. 8, no. 3, pp. 31-37. (In Russ.)]Шишкин М.М., Юлдашева Н.М. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии // Вестник НМХЦ им. Н.И. Пирогова, 2011. Т. 6, № 1. С. 77-81. [Shishkin M.M., Yuldashev N.M. Intravitreal administration of inhibitors of angiogenesis as a stage of gentle vitreoretinal surgery of proliferative diabetic retinopathy. Vestnik NMHTS im. N.I. Pirogova = Bulletin SMSC named by N.I. Pirogov, 2011, Vol. 6, no. 1, pp. 77-81. (In Russ.)]Шишкин М.М., Юлдашева Н.М. Интравитреальное введение ингибиторов ангиогенеза как этап щадящей витреоретинальной хирургии пролиферативной диабетической ретинопатии // Вестник НМХЦ им. Н.И. Пирогова, 2011. Т. 6, № 1. С. 77-81. [Shishkin M.M., Yuldashev N.M. Intravitreal administration of inhibitors of angiogenesis as a stage of gentle vitreoretinal surgery of proliferative diabetic retinopathy. Vestnik NMHTS im. N.I. Pirogova = Bulletin SMSC named by N.I. Pirogov, 2011, Vol. 6, no. 1, pp. 77-81. (In Russ.)]Agarwal D., Gelman R., Prospero Ponce C., Stevenson W. Christoforidis J.B. Vitreomacular Interface in Diabetic Retinopathy. J. Ophthalmol., 2015, Vol. 2015, p. 392983.Agarwal D., Gelman R., Prospero Ponce C., Stevenson W. Christoforidis J.B. Vitreomacular Interface in Diabetic Retinopathy. J. Ophthalmol., 2015, Vol. 2015, p. 392983.Schlingemann R.O., van Hinsbergh V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br. Ophthalmol., 1997, Vol. 81, no. 6, рр. 501-512.Schlingemann R.O., van Hinsbergh V.W. Role of vascular permeability factor/ vascular endothelial growth factor in eye disease. Br. Ophthalmol., 1997, Vol. 81, no. 6, рр. 501-512.Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites flui. Science., 1983, Vol. 219, no. 4587, рр. 983-985.Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites flui. Science., 1983, Vol. 219, no. 4587, рр. 983-985.Bhisitkul R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., 2006, Vol. 90, no. 12, рр. 1542-1547.Bhisitkul R.B. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., 2006, Vol. 90, no. 12, рр. 1542-1547.Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 1998, Vol. 273, no. 11, рр. 6417-6423.Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem., 1998, Vol. 273, no. 11, рр. 6417-6423.Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D’Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor / vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun., 1993, Vol. 193, no. 2, рр. 631-638.Adamis A.P., Shima D.T., Yeo K.T., Yeo T.K., Brown L.F., Berse B., D’Amore P.A., Folkman J. Synthesis and secretion of vascular permeability factor / vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem. Biophys. Res. Commun., 1993, Vol. 193, no. 2, рр. 631-638.Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol., 1995, Vol. 113, no. 12, рр. 1538-1544.Aiello L.P., Northrup J.M., Keyt B.A., Takagi H., Iwamoto M.A. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch. Ophthalmol., 1995, Vol. 113, no. 12, рр. 1538-1544.Ferrara N., Gerber H.P., LeCouter J. N. The biology of VEGF and its receptors. Nat. Med., 2003, Vol. 9, no. 6, рр. 669-676.Ferrara N., Gerber H.P., LeCouter J. N. The biology of VEGF and its receptors. Nat. Med., 2003, Vol. 9, no. 6, рр. 669-676.Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest., 1998, Vol. 78, no. 8, pp. 1017-1027.Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes. Lab Invest., 1998, Vol. 78, no. 8, pp. 1017-1027.Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab. Invest., 1996, Vol. 74, no. 4, рр. 819-825.Murata T., Nakagawa K., Khalil A., Ishibashi T., Inomata H., Sueishi K. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab. Invest., 1996, Vol. 74, no. 4, рр. 819-825.Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch. Ophthalmol., 2001, Vol. 119, no. 6, рр. 861-866.Gilbert R.E., Vranes D., Berka J.L., Kelly D.J., Cox A., Wu L.L., Stacker S.A., Cooper M.E. Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. Arch. Ophthalmol., 2001, Vol. 119, no. 6, рр. 861-866.Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF- induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci., 2002, Vol. 43, no. 3, рр. 849-857.Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF- induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci., 2002, Vol. 43, no. 3, рр. 849-857.Wong C.G., Rich K.A., Liaw L.H., Hsu H.T., Berns M.W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr. Eye. Res., Vol. 22, no. 2, pp. 140-147.Wong C.G., Rich K.A., Liaw L.H., Hsu H.T., Berns M.W. Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit. Curr. Eye. Res., Vol. 22, no. 2, pp. 140-147.Tolentino M.J., McLeod D.S., Taomoto M., Otsuji T., Adamis A.P., Lutty G.A. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol., 2002, Vol. 133, no. 3, рр. 373-385.Tolentino M.J., McLeod D.S., Taomoto M., Otsuji T., Adamis A.P., Lutty G.A. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am. J. Ophthalmol., 2002, Vol. 133, no. 3, рр. 373-385.Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Hung V.N., Aiello L.M., Napoleone F., George L. Vascular endothelial growth factor in ocular fluid patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med., 1994, Vol. 331, no. 22, рр. 1480-1487.Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Hung V.N., Aiello L.M., Napoleone F., George L. Vascular endothelial growth factor in ocular fluid patients with diabetic retinopathy and other retinal disorders. N. Eng. J. Med., 1994, Vol. 331, no. 22, рр. 1480-1487.Adamis A.P., Miller J.W., Bernal M.T., D’Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 1994, Vol. 118, no. 4, рр. 445-450.Adamis A.P., Miller J.W., Bernal M.T., D’Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol., 1994, Vol. 118, no. 4, рр. 445-450.Amin R.H., Frank R.N., Kennedy A., Eliott D., Puklin J.E., Abrams G.W. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis Sci., 1997, Vol. 38, no. 1, рр. 36-47.Amin R.H., Frank R.N., Kennedy A., Eliott D., Puklin J.E., Abrams G.W. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest. Ophthalmol. Vis Sci., 1997, Vol. 38, no. 1, рр. 36-47.Sack R.A., Conradi L., Krumholz D., Beaton A., Sathe S., Morris C. Membrane array characterization of 80 chemokines, cytokines and growth factor in open and closed eye tears: angiogenin and other defense system constituents. Invest. Ophthalmol. Vis Sci., 2005, Vol. 46, no. 4, рр. 1228-1238.Sack R.A., Conradi L., Krumholz D., Beaton A., Sathe S., Morris C. Membrane array characterization of 80 chemokines, cytokines and growth factor in open and closed eye tears: angiogenin and other defense system constituents. Invest. Ophthalmol. Vis Sci., 2005, Vol. 46, no. 4, рр. 1228-1238.Funatsu H., Yamashita H., Nakamura S., Mimura T., Eguchi S., Noma H., Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 2006, Vol. 113, no. 2, рр. 294-301.Funatsu H., Yamashita H., Nakamura S., Mimura T., Eguchi S., Noma H., Hori S. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 2006, Vol. 113, no. 2, рр. 294-301.Nishikiori N., Osanai M., Chiba H., Kojima T., Mitamura Y., Ohguro H., Sawada N. Glial Cell-Derived Cytokines Attenuate the Breakdown of Vascular Integrity in Diabetic. Diabetes., 2007, Vol. 56, no. 5, рр. 1333-1340.Nishikiori N., Osanai M., Chiba H., Kojima T., Mitamura Y., Ohguro H., Sawada N. Glial Cell-Derived Cytokines Attenuate the Breakdown of Vascular Integrity in Diabetic. Diabetes., 2007, Vol. 56, no. 5, рр. 1333-1340.Tripathi R.C., Li J., Tripathi B.J., Chalam K.V., Adamis A.P. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology, 1998, Vol. 105, no. 2, рр. 232-237.Tripathi R.C., Li J., Tripathi B.J., Chalam K.V., Adamis A.P. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology, 1998, Vol. 105, no. 2, рр. 232-237.Noma H., Funatsu H., Yamashita H., Kitano S., Mishima H.K., Hori S. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol., 2002, Vol. 120, no. 8, рр. 1075-1080.Noma H., Funatsu H., Yamashita H., Kitano S., Mishima H.K., Hori S. Regulation of angiogenesis in diabetic retinopathy: possible balance between vascular endothelial growth factor and endostatin. Arch. Ophthalmol., 2002, Vol. 120, no. 8, рр. 1075-1080.Shinoda K., Ishida S., Kawashima S., Wakabayashi T., Uchita M., Matsuzaki T., Takayama M., Shinmura K., Yamada M. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-661.Shinoda K., Ishida S., Kawashima S., Wakabayashi T., Uchita M., Matsuzaki T., Takayama M., Shinmura K., Yamada M. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-661.Wang J., Chen S., Jiang F., You C., Mao C., Yu J., Han J., Zhang Z., Yan H. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-651.Wang J., Chen S., Jiang F., You C., Mao C., Yu J., Han J., Zhang Z., Yan H. Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. Curr Eye Res., 2000, Vol. 21, no. 2, pp. 655-651.Funatsu H., Yamashita H., Noma H., Mimura T., Sakata K., Hori S. Risk evaluation of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin ll. Br. J. Ophthalmol., 2004, Vol. 88, no. 8, рр. 1064-1068.Funatsu H., Yamashita H., Noma H., Mimura T., Sakata K., Hori S. Risk evaluation of vitreous surgery for proliferative diabetic retinopathy based on vitreous level of vascular endothelial growth factor and angiotensin ll. Br. J. Ophthalmol., 2004, Vol. 88, no. 8, рр. 1064-1068.Funatsu H., Yamashita H., Mimura T., Noma H., Nakamura S., Hori S. Risk evalution of outcome of vitreous surgery based on vitreous levels of cytokines. Eye, 2007, Vol. 21, no. 3, рр. 377-382.Funatsu H., Yamashita H., Mimura T., Noma H., Nakamura S., Hori S. Risk evalution of outcome of vitreous surgery based on vitreous levels of cytokines. Eye, 2007, Vol. 21, no. 3, рр. 377-382.

The authors declare that there are no conflicts of interest present.